HEPYX

For investing or partnering interest, please click here

Our aim is to save patients by resolving acute-on-chronic liver failure

Acute-on-chronic liver failure (ACLF) is a life-threatening complication in advanced liver disease, where patients suddenly experience acute hepatic decompensation with one or more organ failures.

High mortality rates can be significantly reduced if ACLF can be resolved.

1Moreau R et al, CANONIC Study Investigators of the EASL–CLIF Consortium. ACLF is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013 Jun.

Developing a life-saving treatment for ACLF

We are evaluating our toll-like receptor 4 (TLR4) antagonist alone and in combination with granulocyte colony-stimulating factor (G-CSF) to resolve ACLF 1-2.

  • By blocking TLR4, we inhibit endotoxin-induced inflammation and reduce the cytokine storm which causes liver damage and organ failure.
  • A synergistic combination with G-CSF enables subsequent liver regeneration.

Our Pipeline

Phase 2 study ongoing (UK). This multi-center, randomized, double blind study will enrol 78 patients with alcohol-induced ACLF 1-2 . Initial data readout is expected in H2-2027 with final readout in H2-2028.

The trial is being run by the A-Tango consortium, led by Yaqrit’s CMO and Founder Prof. Rajiv Jalan as scientific coordinator, with clinical study supervisor Dr. Cornelius Engelmann.

Our Leadership

Hepyx currently benefits form key members of Yaqrit’s leadership team. In time permanent Hepyx appointments will be made.
Prof. Rajiv Jalan, Ph.D. Prof. Rajiv Jalan, Ph.D. Chair, Founder, CMO/CSO

Professor of Hepatology and Head of the Liver Failure Group at UCL. Key opinion leader in advanced liver disease and ACLF, extensively published

Troels Jordansen Troels Jordansen Chief Executive Officer

Over 35 years in commercial and senior leadership roles in life-sciences with an established track record in funding and growing companies

Karen Church, Ph.D. Karen Church, Ph.D. Head of RA, QA, and Clinical Operations

Clinical and regulatory specialist. Overseen submission of 27 NDAs/MMAs/PMAs and hundreds of INDs/CTAs

Carrie Morgan Carrie Morgan SVP Clinical Operations

More than 35 years clinical operations experience including overseeing phase 2/3 studies and securing funding in research innovation

Michal Kowalski Michal Kowalski SVP Operations

Expert in scaling biotech start-ups and business engineering leveraging technical expertise and commercial acumen for strategic growth

Mary-Ann Chang, CFA Mary-Ann Chang, CFA SVP Communications and Strategy

Strategic communicator with more than 25 years of experience in the life-science industry, covering IR, communication and healthcare investment